Neurotech International (NTI) Price & Analysis

Compare

11 Followers

NTI Stock Chart & Stats

AU$0.02

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.02

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.05

Previous CloseN/A

Volume11.09K

Average Volume (3M)768.84K

Market Cap

AU$18.15M

Enterprise ValueAU$11.11M

Total Cash (Recent Filing)AU$3.03M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.82

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,296,313,100

10 Day Avg. Volume770,041

30 Day Avg. Volume768,844

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)5.26

Price to Sales (P/S)6.36

P/FCF Ratio-1.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)AU$6.58M

Bulls Say, Bears Say

Bulls Say

Minimal Leverage / Zero DebtZero reported debt eliminates fixed interest obligations and materially reduces near-term solvency risk. This durable capital structure gives management flexibility to prioritize R&D and clinical spend without immediate debt-servicing constraints, though equity funding may still be required.

FY2025 Revenue ReboundA rebound to ~A$2.44m in FY2025 from a near-zero base signals early commercial receipts or milestone recognition, showing initial market traction or program monetization. If sustained, this trend could validate development progress and reduce absolute funding dependence over time.

Specialized Neurological R&D FocusA focused pipeline in neurology and neurodevelopmental disorders builds specialized scientific expertise and IP potential in high unmet-need markets. This strategic concentration can create durable differentiation and clearer program prioritization if clinical outcomes advance.

Bears Say

Persistent Heavy Operating LossesOperating and net losses far exceed current revenue, producing deeply negative margins. Persistent losses erode capital, constrain strategic options and require continual external funding, which increases dilution risk and limits sustainable investment until margins improve.

Worsening Free Cash Flow / High BurnFree cash flow nearly doubled its deficit year-over-year, reflecting accelerating cash burn as activities ramp. This structurally negative cash generation requires recurrent financing, heightens execution risk for clinical programs and pressures management to secure durable funding sources.

Materially Reduced Equity BaseEquity fell sharply year-over-year, indicating capital consumption and/or dilution. A diminished equity buffer reduces the balance-sheet's ability to absorb further losses, makes future capital raises more dilutive, and weakens financial resilience over the medium term.

Neurotech International News

Neurotech Wins Ethics Approval for Pivotal Phase 3 Autism Trial of NTI164

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has secured Human Research Ethics...

3d ago

NTI

Neurotech Advances Lead Paediatric Neurology Drug NTI164 with New FDA Designation, Data and Funding

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International reported a pivotal quarter marked...

6d ago

NTI

Neurotech’s NTI164 PANS Data Published in Leading Journal, Bolstering Paediatric Neuro Portfolio

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has reported that clinical and mechanistic data...

21d ago

NTI

Neurotech Issues New Shares, Affirms Regulatory Compliance

Neurotech International ( ($AU:NTI) ) has issued an update. Neurotech International has issued new ordinary fully paid shares...

1M ago

NTI

Neurotech Seeks ASX Quotation for 246.7 Million New Shares

An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has applied to the ASX...

1M ago

NTI

Neurotech Director’s 5 Million Options Lapse, Reducing Potential Equity Exposure

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has disclosed a change in director Gerald...

1M ago

NTI

Neurotech Options Lapse, Streamlining Capital Structure

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International Limited has allowed 5 million unlisted options,...

1M ago

NTI

Neurotech International Secures $4 Million to Advance Paediatric Neurological Treatments

Neurotech International ( ($AU:NTI) ) has shared an announcement. Neurotech International has secured binding commitments for a $4...

2M ago

NTI

Neurotech International Initiates Trading Halt for Capital Raising Announcement

Neurotech International ( ($AU:NTI) ) has shared an update. Neurotech International Limited has requested a trading halt on...

2M ago

NTI

Neurotech International’s AGM Reflects Strong Shareholder Support

Neurotech International ( ($AU:NTI) ) just unveiled an announcement. Neurotech International Limited held its Annual General Meeting, where...

3M ago

NTI

NTI FAQ

What was Neurotech International Ltd.’s price range in the past 12 months?

Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.

What is Neurotech International Ltd.’s market cap?

Neurotech International Ltd.’s market cap is AU$18.15M.

When is Neurotech International Ltd.’s upcoming earnings report date?

Neurotech International Ltd.’s upcoming earnings report date is Mar 03, 2026 which is in 26 days.

How were Neurotech International Ltd.’s earnings last quarter?

Neurotech International Ltd. released its earnings results on Aug 29, 2025. The company reported -AU$0.003 earnings per share for the quarter, beating the consensus estimate of -AU$0.005 by AU$0.002.

Is Neurotech International Ltd. overvalued?

According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neurotech International Ltd. pay dividends?

Neurotech International Ltd. does not currently pay dividends.

What is Neurotech International Ltd.’s EPS estimate?

Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neurotech International Ltd. have?

Neurotech International Ltd. has 1,296,313,100 shares outstanding.

What happened to Neurotech International Ltd.’s price movement after its last earnings report?

Neurotech International Ltd. reported an EPS of -AU$0.003 in its last earnings report, beating expectations of -AU$0.005. Following the earnings report the stock price went up 7.692%.

Which hedge fund is a major shareholder of Neurotech International Ltd.?

Currently, no hedge funds are holding shares in AU:NTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neurotech International Stock Smart Score

Underperform

Fundamentals

Return on Equity

-142.71%

Trailing 12-Months

Asset Growth

-73.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurotech International Ltd.

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.